An increase in cell number at completion of therapy may develop as an indicator of early relapse

  title={An increase in cell number at completion of therapy may develop as an indicator of early relapse},
  author={Katharina Pachmann and Robert Dengler and Kurt Lobodasch and Frank Fr{\"o}hlich and Torsten Kroll and Matthias Rengsberger and Rene Schubert and Ulrich A. Pachmann},
  journal={Journal of Cancer Research and Clinical Oncology},
PurposeTreatment efficiency of adjuvant therapy in breast cancer is only revealed after several years by statistical evaluation and gives no answer for the individual patient. We here present a method to analyze the response to adjuvant chemotherapy online in individual patients.Methods/resultsIn 25 consecutive non-metastatic primary breast cancer patients adjuvant fluorouracil/epirubicin/cyclophosphamid (FEC) or EC followed by taxane (EC-T) or cyclophosphamid/methotrexate/fluorouracil (CMF… 
Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse.
  • K. Pachmann, O. Camara, K. Höffken
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
The results show that peripherally circulating tumor cells are influenced by systemic chemotherapy and that an increase (even after initial response to therapy) of 10-fold or more at the end of therapy is a strong predictor of relapse and a surrogate marker for the aggressiveness of the tumor cells.
The role of circulating tumor cells in breast cancer diagnosis and prediction of therapy response.
Standardization of methods will allow for the uniform detection of microscopic disease in the peripheral blood of patients with MBC and provide prognostic information that will allow appropriate risk stratification and modification of the current staging system for advanced disease.
Review: Biological relevance of disseminated tumor cells in cancer patients
This review will focus on bone marrow (BM) as the main tumor entities in Europe and the United States and present currently available methods for the detection and characterization of disseminated tumor cells (DTC).
Circulating epithelial tumor cells as a prognostic tool for malignant melanoma
Quantification of CETCs could prove to be a prognostic marker for patients with melanoma receiving interferon immunotherapy and whether these results are applicable to other immunotherapies, for example, immune checkpoint inhibition.
Circulating Tumor Cells: Detection Methods and Potential Clinical Application in Breast Cancer
A paradigm shift may be introduced in the treatment strategy, from the present one that is based only on primary tumor characteristics to the future one that considers molecular characterization of CTCs as well.
Clinical significance of circulating tumor cells in breast cancer patients
The results suggested that CTC assessment could be an indication of the disease progression and analysis of the properties of CTCs is likely to provide new insights into the biology of breast cancer and contribute to defining novel treatments and better prediction of clinical outcomes.
Treatment of advanced solid tumours with NSAIDs: Correlation of quantitative monitoring of circulating tumour cells and positron emission tomography-computed tomography imaging
It may be concluded that patients with solid tumours benefit from serial quantification of CTCs in addition to imaging, as this combination of techniques provides a more sensitive result than imaging alone.
Quantification of circulating melanoma cells
Overall, this study has identified MCAM positivity as a CTC marker associated with disease progression which may be useful in improving prognostic testing and disease management in melanoma patients.
Hormone receptor status, erbB2 expression and cancer stem cell characteristics of circulating tumor cells in breast cancer patients.
The most important predictor for disease-free and overall survival of breast cancer patients is the presence of axillary lymph node metastasis and it appears that the CTC, and consequently the metastatic cells, may have a very different hormone and erbB2 status.


Increase in number of circulating disseminated epithelial cells after surgery for non-small cell lung cancer monitored by MAINTRAC® is a predictor for relapse: A preliminary report
It is considered that patients with adenocarcinoma and a continuous increase of CEC after complete resection for lung cancer are at an increased risk of early relapse.
Circulating Tumor Cells in Patients with Breast Cancer Dormancy
There appears to be a balance between tumor replication and cell death for as long as 22 years in dormancy candidates and it is concluded that this is one mechanism underlying tumor dormancy.
Ineffectiveness of Doxorubicin Treatment on Solitary Dormant Mammary Carcinoma Cells or Late-developing Metastases
Testing the hypothesis that dormant tumor cells would not be killed by cytotoxic chemotherapy that targets actively dividing cells, and that the late development of metastases from D2.0R/R cells would be inhibited by chemotherapy that effectively inhibited D2A1/R metastases, found it unlikely that these cells would give rise to metastases at a later date.
Circulating tumor cells, disease progression, and survival in metastatic breast cancer.
The number of circulating tumor cells before treatment is an independent predictor of progression-free survival and overall survival in patients with metastatic breast cancer.
[Detection of disseminated tumor cells in bone marrow--currently of no practical therapeutic value].
It is too early to say whether the detection of disseminated tumour cells in the bone marrow can be used as a prognostic factor with an impact on therapeutic strategies, and a lack of standardization means that the results of the individual studies are not directly comparable.
Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer.
The detection of CK-19 mRNA-positive cells in the peripheral blood after adjuvant chemotherapy may be of clinical relevance for patients with early breast cancer and less than four involved axillary lymph nodes.
30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study
When delivered optimally, CMF benefits patients at risk of relapse of distant disease without evidence of detrimental effects in any of the examined subgroups.
Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity
Circulating tumor cells seem to be nonproliferating cells that persist during chemotherapy and are linked to disease progression and elevated tumor marker concentrations in patients with metastatic breast cancer.
A pooled analysis of bone marrow micrometastasis in breast cancer.
The presence of micrometastasis in the bone marrow at the time of diagnosis of breast cancer is associated with a poor prognosis.